Amgen INC Form 4 insider transactions

Amgen's CEO, Robert Bradway, disposed of 2,294 shares of common stock on May 2, 2024, to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Nancy Grygiel, SVP & CCO of Amgen, reported the sale of 2,117 shares of common stock and the vesting of Restricted Stock Units (RSUs) on May 3, 2024.

Esteban Santos, EVP of Operations at Amgen, reports the disposition of 606 shares of common stock to cover tax obligations related to vested Restricted Stock Units (RSUs) and the acquisition of shares through the company's 401(k) plan.

David M. Reese, EVP & Chief Technology Officer of Amgen, reports the disposition of 650 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

Amgen's SVP of Human Resources, Derek Miller, disposed of 152 shares of common stock on May 2, 2024, to cover tax obligations related to vested Restricted Stock Units (RSUs).

Nancy Grygiel, SVP & CCO of Amgen, reports the disposition of 114 shares of common stock to cover tax obligations related to vesting Restricted Stock Units (RSUs).

Peter H. Griffith, EVP & CFO of Amgen, disposed of 682 shares of common stock on May 2, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.

Jonathan P. Graham, EVP & General Counsel & Secretary of Amgen Inc., disposed of 591 shares of common stock on May 2, 2024, to satisfy tax withholding obligations related to vested restricted stock units.

Murdo Gordon, EVP at Amgen, disposed of 758 shares of common stock to cover tax obligations related to vested Restricted Stock Units (RSUs).

Derek Miller, SVP of Human Resources at Amgen, disposed of 71 shares of common stock on April 30, 2024, to satisfy tax withholding obligations related to vested restricted stock units.

Rachna Khosla, SVP of Business Development at Amgen, reports a transaction involving common stock on April 30, 2024, resulting in a beneficial ownership of 8,142 shares.

Jonathan P. Graham, EVP & General Counsel & Secretary of Amgen Inc., reports disposing of 686 shares of common stock to cover tax obligations related to vested restricted stock units.

Nancy Grygiel, SVP & CCO of Amgen, reports the disposition of 106 shares of common stock to cover tax obligations related to vesting Restricted Stock Units (RSUs) and dividend equivalents, while also holding 12,114 shares directly and 99.9653 shares indirectly through a 401(k) plan.

EVP of Operations at Amgen, Esteban Santos, reports disposition of shares to cover tax obligations and ongoing holdings including restricted stock units and shares in the 401(k) plan.

David M. Reese, EVP & Chief Technology Officer of Amgen, reports the disposition of 690 shares of common stock to cover tax obligations related to vesting restricted stock units.

Peter Griffith, EVP & CFO of Amgen, disposed of 603 shares of common stock on April 30, 2024, to satisfy tax withholding obligations related to vested Restricted Stock Units.

Murdo Gordon, EVP at Amgen, disposed of 753 shares of common stock on April 30, 2024, to satisfy tax withholding obligations related to vested Restricted Stock Units.

Matthew C. Busch, VP, Finance & CAO of Amgen Inc., reports a transaction involving common stock due to tax withholding on vesting Restricted Stock Units (RSUs).

Amgen's Chairman, CEO, and President, Robert A. Bradway, disposed of 2,282 shares of common stock to cover tax obligations related to vested Restricted Stock Units (RSUs).

Esteban Santos, EVP of Operations at Amgen, reports the disposition of shares to cover tax obligations related to vesting restricted stock units and an acquisition of shares through the company's 401(k) plan.

David M. Reese, EVP & Chief Technology Officer of Amgen, disposed of 6,202 shares of common stock on March 18, 2024, to cover tax obligations related to vested Restricted Stock Units.

Derek Miller, SVP of Human Resources at Amgen, reports the disposition of 475 shares of common stock to cover tax obligations related to vesting restricted stock units.

Rachna Khosla, SVP of Business Development at Amgen, disposed of 438 shares of common stock on March 18, 2024, to cover tax obligations related to vested Restricted Stock Units (RSUs).

Nancy A. Grygiel, SVP & CCO of Amgen Inc., reports a disposition of shares to cover tax obligations related to vested Restricted Stock Units (RSUs) and updates holdings in the company's 401(k) plan.

Peter Griffith, EVP & CFO of Amgen, disposed of 5,168 shares of common stock to cover tax obligations related to vested Restricted Stock Units (RSUs).

Jonathan P. Graham, EVP & General Counsel & Secretary of Amgen Inc., disposed of 5,879 shares of common stock on March 18, 2024, to cover tax obligations.

EVP Murdo Gordon disposed of 6,461 shares of Amgen stock on March 18, 2024, to satisfy tax withholding obligations related to vested restricted stock units.

Matthew C. Busch, VP of Finance & CAO at Amgen, filed a Form 4 disclosing changes in beneficial ownership of Amgen stock due to the disposition of shares to cover tax obligations related to vesting restricted stock units.

Amgen's Chairman, CEO, and President, Robert A. Bradway, disposed of 20,560 shares of common stock on March 18, 2024, to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

EVP Esteban Santos reports acquisition of Amgen stock through restricted stock units, dividend equivalents, and a 401(k) plan.